Ahmed Mazen Safar, MD, MS

Associate Member

Research Program:

Cancer Biology

Faculty Rank:

Associate Professor of Medicine

Campus:

University of Arkansas for Medical Sciences

College:

College of Medicine

Department:

Medicine

Cancer Research Interest

Disease Site Focus: Thoracic/ Lung, GI
Research Focus Area: Carcinogenesis, Treatment
Type of Research: Translational, Clinical
Research Keywords: tumor immunology, carcinogensis, tumor biomarkers
Research Interest Statement: I am working on identifying the molecular underpinning of metastatic cancer and to determine if this phenomenon is a gain of function or the 'retention' of function. Additionally, we are studying the possibility to determine the probability of cure shortly after starting immune therapy for metastatic cancer. Such measure could then be used to guide treatment selection, duration and inform prognostication activity for the patient and other health professionals. Finally, we are applying the current understanding of cancer immunology to see if surgical metastasectomy is curative by providing the debulking function only for immune-prone cancers. Once confirmed, this would be invaluable in guiding surgeons, oncologists and patients in decision making when resection of oligometastatic cancer is considered.

Rego R, Safar A. Targeted BRAF Inhibitor Therapy Induces Remission of Unresectable Ampullary Adenocarcinoma. ACG case reports journal. 2022 9(8):e00844. PMID: 36061246. PMCID: PMC9433074.
Atwal D, Safar AM, Govindarajan R, Makhoul I. Severe first infusion reaction related to cetuximab in cancer patients in Arkansas. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2019 25(5):1130-1134. PMID: 29890919.